What is Aktis Oncology, Inc. Common stock (AKTS) stock price today?

Aktis Oncology, Inc. Common stock (AKTS) currently trades at $18.75 per share. The stock has a market capitalization of $1.03B and a P/E ratio of —x.

Is AKTS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Aktis Oncology, Inc. Common stock has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Aktis Oncology, Inc. Common stock's revenue and earnings?

Aktis Oncology, Inc. Common stock has trailing twelve-month (TTM) revenue of $6.50M with profit margins of 0.00%. Earnings per share (EPS) is $-1.21.

AKTS

Aktis Oncology, Inc. Common stock

NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY

$18.75

+0.16% today

Updated 2026-04-30

Market cap

$1.03B

P/E ratio

—

P/S ratio

159.27x

EPS (TTM)

$-1.21

Dividend yield

—

52W range

$15 – $29

Volume

0.4M

Market cap

$1.03B

P/E ratio

—

P/S ratio

159.27x

EPS (TTM)

$-1.21

Dividend yield

—

52W range

$15 – $29

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$32.50

+73.33%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 100.40% QoQ

Risks

- Thin margins at 0.00%

- Negative free cash flow $-19.39M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$27.12M	$1.49M	$6.50M	$6.50M
Net income	$-17.93M	$-28.64M	$-43.98M	$-63.73M	$-15.14M
EPS	—	—	—	—	$-1.21
Free cash flow	$-20.43M	$-33.77M	$11.90M	$-73.71M	$-19.39M
Profit margin	—	-105.60%	-2,957.63%	-980.93%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2024-01-29	SHEALY, JEFFREY B.	Buy	1,310,000	$0.50
2024-01-29	GEISS, ARTHUR	Buy	50,000	$0.50
2024-01-29	BOLLER, KENNETH	Buy	60,000	$0.50

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AKTS	$1.03B	27	6.3	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Aktis Oncology, Inc. Common stock trades at $18.75. Our Smart Value Score of 27/100 indicates the stock is weak. TTM revenue stands at $6.50M.

Frequently asked questions

What is Aktis Oncology, Inc. Common stock's stock price?

Aktis Oncology, Inc. Common stock (AKTS) trades at $18.75.

Is Aktis Oncology, Inc. Common stock overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Aktis Oncology, Inc. Common stock (AKTS)?

The analyst target price is $32.50, representing +73.3% upside from the current price of $18.75.

What is Aktis Oncology, Inc. Common stock's revenue?

TTM revenue is $6.50M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio159.27x

ROE-29.40%

Beta—

50D MA$18.79

200D MA$19.24

Shares out0.05B

Float0.03B

Short ratio—

Avg volume0.4M

Performance

1 week+10.19%

1 month+3.45%

3 months-5.82%

YTD—

1 year—

3 years—

5 years—

Compare

AKTS vs LLY →AKTS vs JNJ →AKTS vs ABBV →Stock screener →